METHODS: Patients starting ranolazine (n = 16) were evaluated for short-term GV, haemoglobin 1Ac (Hb1Ac) levels, endothelial-dependent flow-mediated vasodilation (FMD), and oxidative stress levels at enrolment and after 3-month follow-up. The same measurements were collected from 16 patients with CCS and T2D that did not receive ranolazine, matched for age, gender, and body mass index.
RESULTS: A significant decline in Hb1Ac levels was reported after 3-month ranolazine treatment (mean change -0.60%; 2-way ANOVA p = 0.025). Moreover, among patients receiving ranolazine, short-term GV indexes were significantly improved over time compared with baseline (p = 0.001 for time in range; 2-way ANOVA p = 0.010). Conversely, no significant changes were reported in patients without ranolazine. Finally, greater FMD and lower oxidative stress levels were observed in patients on ranolazine at 3 months.
CONCLUSIONS: Ranolazine added to standard anti-ischemic and glucose-lowering therapy demonstrated benefit in improving the glycemic status of patients with T2D and CCS. How this improvement contributes to the overall myocardial benefit of ranolazine requires further studies.
方法:对开始服用雷诺嗪的患者(n=16)进行短期GV评估,血红蛋白1Ac(Hb1Ac)水平,内皮依赖性血流介导的血管舒张(FMD),招募时和3个月随访后的氧化应激水平。从未接受雷诺嗪的16例CCS和T2D患者中收集相同的测量值,年龄相匹配,性别,和体重指数。
结果:雷诺嗪治疗3个月后,Hb1Ac水平显着下降(平均变化-0.60%;双向方差分析p=0.025)。此外,在接受雷诺嗪的患者中,与基线相比,短期GV指数随时间显著改善(时间范围p=0.001;双向方差分析p=0.010).相反,没有雷诺嗪的患者无显著变化.最后,在服用雷诺嗪3个月的患者中观察到更高的FMD和更低的氧化应激水平.
结论:雷诺嗪添加到标准抗缺血降糖治疗中,在改善T2D和CCS患者的血糖状态方面显示出益处。这种改善如何有助于雷诺嗪的整体心肌益处需要进一步研究。